# Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/clinical-activity-and-safety-of-simlukafusp-alfa-an-engineered-interleukin-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Antoîne Italiano,Loïc Verlingue,Hans Prenen,Eva Guerra,Diégo Tosi,Ruth Perets,Iwona Ługowska,В. Моисеенко,Mahmut Gümüş,Çağatay Arslan,Colin R. Lindsay,Muriel Richard,David Dejardin,Christophe Boetsch,Anton Kraxner,Stefan Evers,T. Vardar,Nino Keshelava,Volker Teichgräber,Rafał Dziadziuszko |
| Citations | 24 |
| DOI | 10.1200/jco.2021.39.15_suppl.5510 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3172336768 |
| Type | conference-abstract |
| Year | 2021 |

## Paper authors

- [В. Моисеенко](https://scholariq.org/researchers/a5112141652/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Paper topics

- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.